< Back to all clusters
[HEALTH] · Brazil · 61 sources

started · updated

Brazil Ministry of Health requests GLP-1 weight-loss drugs for SUS

The Brazilian Ministry of Health has formally requested that the National Commission for the Incorporation of Technologies in the Unified Health System (Conitec) evaluate including GLP-1 weight-loss medications in the SUS drug list. The proposal specifically targets the evaluation of semaglutide and liraglutide, noting that these active ingredients no longer have patent protection.

The The Ministry cited a significant rise in obesity prevalence in Brazil, which grew from 11.8% in 2006 to 25.7% in 2024. Officials argued that providing long-term access to these therapies could reduce mortality, improve quality of life, and lower overall healthcare costs. This move aligns with World Health Organization guidelines regarding equitable access to obesity treatments.

The request follows a previous rejection by Conitec in August due to high financial impact. However, the Ministry claims the economic landscape has changed, noting that increased market competition has reduced the retail cost of these medications by approximately 70% in less than a year. Currently, 25 weight-loss pens are registered in Brazil, including several national and generic versions.

Entities

Alexandre Padilha · Anvisa · Bestware · Brazil · Conitec · Fernando Yunes · Luiz Inácio Lula da Silva · Mercado Livre · Ministry of Health · Ministério da Saúde · Pague Menos · Panvel

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

3 days ago